Table 2.
Frequency of genetic aberrations by treatment cohort
| Frequency in conventional first-line therapy group | Frequency in conventional second-line therapy group | Frequency in ibrutinib group | |
|---|---|---|---|
| Del17p or TP53 mutation | 6/58 (10.3%) | 3/17 (17.6%) | 9/29 (31.0%) |
| Del13q14.3 | 18/58 (31.0%) | 5/17 (29.4%) | 9/29 (31.0%) |
| Trisomy 12 | 16/58 (27.6%) | 6/17 (35.3%) | 4/29 (13.8%) |
| Del ATM locus | 6/58 (10.3%) | 1/17 (5.9%) | 5/29 (17.2%) |
| Del IGH locus | 7/58 (12.1%) | 3/17 (17.6%) | 1/29 (3.4%) |
| Other | 3/58 (5.2%) | 3/17 (17.6%) | 3/29 (10.3%) |
| Normal | 16/58 (27.6%) | 1/17 (5.9%) | 4/29 (13.7%) |